Q-omics provides the consensus-scored C21orf62 profile across patient tissues and cancer cell-line models. C21orf62 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, C21orf62 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, C21orf62 RNA expression shows 17,989 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KICH, and THYM as cancer lineages where C21orf62 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C21orf62 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C21orf62 survival associations across molecular data types. C21orf62 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C21orf62 RNA expression–survival associations across cancer types. High C21orf62 expression shows unfavorable associations in LGG, but favorable associations in HNSC, KIRC, ACC, SKCM and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for C21orf62 RNA expression.
This table summarizes C21orf62 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for C21orf62. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C21orf62 shows lower tumor expression in KICH, KIRC, LIHC, LUSC, THCA and BRCA. The KICH box plot shows higher C21orf62 RNA expression in normal versus tumor tissue (log2 FC = −4.094, t-test p < 0.001).
This table shows molecular features associated with C21orf62 in patient tissues and cancer cell lines. In patient samples, C21orf62 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, C21orf62 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and OVARY.
